MINNEAPOLIS--(Kevin Wasserstein, Founder & Principal of Mentor Catalyst and Dennis Wahr M.D., President & CEO of Holaira, Conference Co-chairs of the upcoming 12th Annual MedTech Investing Conference (May 8th at the Graves 601 Hotel in Minneapolis), announced today, on behalf of International Business Forum and LifeScience Alley, that Jeffrey E. Shuren, M.D., J.D., Director of Center for Devices and Radiological Health at FDA and Stacy Enxing Seng, President, Vascular Therapies at Covidien are confirmed to deliver keynote presentations at this year’s conference.)--
Covidien’s acquisition strategy and how medtech companies are adapting in the changing healthcare environment.
Stacy Enxing Seng
President, Vascular Therapies
Stacy Enxing Seng, President, Vascular Therapies, is responsible for Covidien’s full portfolio of vascular products, composed of three broad product categories: Venous Vascular (dialysis catheters, compression devices, Deep Vein Thrombosis (DVT) and Chronic Venous Insufficiency (CVI) prevention and intervention devices), Peripheral Vascular (peripheral arterial stents, balloons and atherectomy) and Neurovascular (brain aneurysm embolic coils and flow diversion, thrombectomy and liquid embolics).
Mark Leahey, President of MDMA will be interviewing Jeff who will share insights on key reforms and priorities of the FDA as it relates to the medtech industry.
Jeffrey E. Shuren, M.D., J.D.
Director, Center for Devices and Radiological Health
Jeffrey E. Shuren became the director of the Center for Devices and Radiological Health at the Food and Drug Administration (FDA) in January 2010. He previously served as Acting Center Director, beginning in September 2009. The center is responsible for assuring the safety, effectiveness, and quality of medical devices; assuring the safety of radiation-emitting products (such as cell phones and microwave ovens); and fostering device innovation.
As in past years, the 12th Annual MedTech Investing Conference will combine some of the most interesting, provocative, and compelling speakers with an optimal networking experience for what has been widely recognized as the premier event of the medtech industry. This conference brings together over 400 of the leading investors, corporates, entrepreneurs and relevant service providers to address high-level issues and problems facing the industry with practical and out of the box solutions.
Mr. Wasserstein and Mr. Wahr are supported in the development of this high caliber program by an accomplished Board of Advisors which includes: Josh Baltzell, Managing Director at Split Rock Partners; Mike Berman, President & CEO of Berman Medical; Chad Cornell, Vice President, Corporate Development at Medtronic, Inc.; Doug Fisher, MD, Principal at InterWest Partners; Jan Garfinkle, Founder and Managing Director of Arboretum Ventures; Sami Hamade, Partner at Aberdare Ventures; William T. Harrington, Managing Partner at Osage University Partners; Mark Leahey, President of Medical Device Manufacturers Association; Thomas Letscher, Chairman of Oppenheimer Wolff & Donnelly LLP; David Milne, Managing Partner at SV Life Science Partners; J.P. Peltier, Managing Director, Healthcare at Piper Jaffray & Co.; Mark Scholtes, Partner at PricewaterhouseCooper; Dan Sheehan, President of Covidien Ventures; Jonathan Silverstein, General Partner of OrbiMed Advisors, LLC; Kathleen A. Tune, Partner at Thomas, McNerney & Partners; Dale Wahlstrom, President & CEO of Life Science Alley and BioBusiness Alliance of Minnesota.
This year’s Sponsors for the MedTech Investing Conference include Oppenheimer Wolff & Donnelly, Piper Jaffray & Co., PricewaterhouseCoopers, Robins Kaplan Miller Ciresi, Medpace Medical Device, Baker Tilly Virchow Krause, Allen Executive Search, EvaluateMedtech, BSI Group America Inc., Minnetronix and Medical Device Manufacturers Association (MDMA).
For more information on this unique event and to sign up to participate visit www.medtechconference.com, or contact Danielle Pappas, Executive Producer of International Business Forum, at firstname.lastname@example.org.